MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Minerva Neurosciences Inc

Fechado

1.65 1.85

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.57

Máximo

1.68

Indicadores-chave

By Trading Economics

P/E

Médio do Setor

1.843

39.564

EPS

-0.5

Funcionários

8

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.3M

9.6M

Abertura anterior

-0.2

Fecho anterior

1.65

Minerva Neurosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de jul. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FCC Approves U.S. Cellular Sale to T-Mobile

11 de jul. de 2025, 17:28 UTC

Grandes Movimentos do Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 de jul. de 2025, 16:57 UTC

Ganhos

BASF Cuts Outlook on Global Economy Uncertainty

11 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 de jul. de 2025, 19:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 de jul. de 2025, 19:45 UTC

Conversa de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 de jul. de 2025, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 de jul. de 2025, 18:18 UTC

Conversa de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 de jul. de 2025, 17:35 UTC

Conversa de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 de jul. de 2025, 17:26 UTC

Conversa de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 de jul. de 2025, 16:53 UTC

Conversa de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 de jul. de 2025, 16:42 UTC

Ganhos

BASF Cuts Outlook on Global Economic Uncertainty

11 de jul. de 2025, 16:08 UTC

Conversa de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 de jul. de 2025, 16:05 UTC

Ganhos

BASF Will Publish Half-Year Results on July 30

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 de jul. de 2025, 16:03 UTC

Ganhos

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 de jul. de 2025, 16:02 UTC

Ganhos

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 de jul. de 2025, 16:01 UTC

Ganhos

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 de jul. de 2025, 16:00 UTC

Ganhos

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 de jul. de 2025, 15:59 UTC

Ganhos

BASF Cuts 2025 Earnings View

11 de jul. de 2025, 15:58 UTC

Ganhos

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 de jul. de 2025, 15:57 UTC

Ganhos

BASF 2Q EBIT Before Special Items EUR810M

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF 2Q Sales Fell 2.1% on Year

11 de jul. de 2025, 15:53 UTC

Ganhos

BASF 2Q Sales EUR15.77B

11 de jul. de 2025, 15:52 UTC

Ganhos

BASF: This Was in Line With Consensus Estimates

11 de jul. de 2025, 15:52 UTC

Ganhos

BASF 2Q Ebitda Before Special Items EUR1.77B

11 de jul. de 2025, 15:49 UTC

Ganhos

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 de jul. de 2025, 15:41 UTC

Conversa de Mercado

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparação entre Pares

Variação de preço

Minerva Neurosciences Inc Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Informação Financeira

$

Sobre Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.